2026

Pembrolizumab Plus Lenvatinib in Recurrent Gynaecological Clear Cell Carcinoma (LARA): A Multicentre, Single-Arm, Phase 2 Trial (The LANCET Oncology, Feb 2026)

A multinational study led by Principal Investigator A/Prof. David Tan and collaborators from Singapore and South Korea has demonstrated encouraging results for patients with recurrent clear cell ovarian and endometrial

Pembrolizumab Plus Lenvatinib in Recurrent Gynaecological Clear Cell Carcinoma (LARA): A Multicentre, Single-Arm, Phase 2 Trial (The LANCET Oncology, Feb 2026) Read More »